Innoviva, Inc. (INVA)
After hours:
| Previous close | 14.69 |
| Open | 14.69 |
| Bid | 14.94 x 200 |
| Ask | 14.97 x 200 |
| Day's range | 14.69 - 15.02 |
| 52-week range | 11.37 - 16.86 |
| Volume | |
| Avg. volume | 675,384 |
| Market cap | 945.248M |
| Beta (5Y monthly) | 0.57 |
| PE ratio (TTM) | 6.80 |
| EPS (TTM) | 2.20 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 08 Sept 2015 |
| 1y target est | 15.00 |
PR NewswireArmata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has entered into a secured credit agreement with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, "Innoviva"), Armata's largest shareholder. The gross proceeds to be received by the C
GuruFocus.comInnoviva Inc (INVA) Reports Growth Amidst Challenges in Q4 and Full Year 2023 Financial Results
Company Sees 35% Year-Over-Year Growth in Q4 Product Revenues
- Business Wire
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
BURLINGAME, Calif., February 29, 2024--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the fourth quarter and full year ended December 31, 2023 and highlighted select corporate achievements.
